Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.
OBJECTIVE
To evaluate ondansetron as the sole antiemetic in children treated with emetogenic chemotherapy and irradiation.


METHODS
Fifteen children aged 3-11 years were studied. Seven had acute lymphoblastic leukaemia, two acute myeloid leukaemia, two lymphoma and four had other tumours. Ondansetron 5 mg/m2 IV or 4 mg by mouth was given immediately before chemotherapy or radiation treatment and continued eight hourly for 24 hours. Nausea and vomiting was assessed during treatment and for the next 48 hours, and graded using WHO criteria.


RESULTS
Thirty-eight courses of chemotherapy were assessed, 27 severely emetogenic and 11 moderately emetogenic. Two included total body irradiation. The most severe nausea and vomiting was grade 2 (transient vomiting) reported in six children. Nausea and vomiting was abolished on subsequent courses in four of these children by increasing the ondansetron dose frequency to six hourly. The remaining children experienced no nausea or vomiting (n = 7) or only nausea (n = 2). Nausea and vomiting were each completely controlled in 27 courses.


CONCLUSIONS
Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases.
Sullivan
M J
MJ
Department of Paediatrics, Christchurch School of Medicine.
Abbott
G D
GD
Robinson
B A
BA
D002648:Child; D002675:Child, Preschool; D006801:Humans; D016399:Lymphoma, T-Cell / Q000532:radiotherapy*; D009325:Nausea / Q000209:etiology / Q000517:prevention & control; D017294:Ondansetron / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000517:prevention & control; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*
D017294:Ondansetron